MAYNE PHARMA GROUP LIMITED (MYX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MYX - MAYNE PHARMA GROUP LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.39
Index: ASX300 | ALL-ORDS

Mayne Pharma is an Australian pharmaceuticals development and manufacturing company with facilities in Australia and the US. It also provides development and manufacturing services to global clients. It listed in 2007.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$4.45

20 Nov
2024

-0.200

OPEN

$4.64

-4.30%

HIGH

$4.68

74,695

LOW

$4.45

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-218.8
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx388.4 M
Book Value Per Share xxxxxxxxxxxxxxx559.0
Net Operating Cash Flow xxxxxxxxxxxxxxx-9.6 M
Net Profit Margin xxxxxxxxxxxxxxx-43.41 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-30.98 %
Return on Invested Capital xxxxxxxxxxxxxxx-29.16 %
Return on Assets xxxxxxxxxxxxxxx-14.10 %
Return on Equity xxxxxxxxxxxxxxx-30.98 %
Return on Total Capital xxxxxxxxxxxxxxx-13.25 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-17.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx4 M
Long Term Debt xxxxxxxxxxxxxxx35 M
Total Debt xxxxxxxxxxxxxxx39 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx152 M
Price To Book Value xxxxxxxxxxxxxxx0.84

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx20.9 M
Capex % of Sales xxxxxxxxxxxxxxx5.37 %
Cost of Goods Sold xxxxxxxxxxxxxxx229 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx237 M
Research & Development xxxxxxxxxxxxxxx20 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Wilsons

02/09/2024

1

Overweight

$5.93

33.26%

Mayne Pharma reported FY24 revenue in line with Wilsons while margins were a beat.

FY24 was a pivotal year in Mayne Pharma’s business, Wilsons suggests, with a streamlined focus in higher value markets,
demonstrating an ability to claw back revenue and gross profit growth, as well as early evidence of operating leverage.

Management has also worked hard to ‘clean up’ Mayne’s cash flow and accounting, which is a positive development providing the market with more confidence in forecasting and the company's self-funding ability.

Wilsons retains Overweight with revised target of $5.93.

FORECAST
Wilsons forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -22.20 cents.
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -5.30 cents.
Access Extra Coverage Research History >

MYX STOCK CHART

FNArena News on MYX

1
Australian Broker Call *Extra* Edition – Nov 13, 2024

Nov 13 2024 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Sep 23, 2024

Sep 23 2024 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Sep 02, 2024

Sep 02 2024 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Aug 28, 2024

Aug 28 2024 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Jul 09, 2024

Jul 09 2024 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
2
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
3
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
4
CSL Shares Breaking Free

Jul 23 2024 - Technicals
5
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
6
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
7
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
8
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
9
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
10
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps